Regulatory Story
Go to market news section View chart   Print
Allergy Therapeutics PLC  -  AGY   

Total Voting Rights

Released 09:00 30-Nov-2012

RNS Number : 2502S
Allergy Therapeutics PLC
30 November 2012

30 November 2012


Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")


Total Voting Rights


Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the recent exercise of options, the Company's share capital consists of 418,161,314 Ordinary 0.1p shares with voting rights attached (one vote per Ordinary share). The Company has no shares in Treasury therefore the total number of voting rights in Allergy Therapeutics is 418,161,314.


The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Allergy Therapeutics under the FSA's Disclosure and Transparency Rules.



For further information


Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson / Clare Terlouw

FTI Consulting

+44 (0) 207 831 3113

Simon Conway / Susan Stuart / Victoria Foster Mitchell



This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Total Voting Rights - RNS